Please assess the completion status of the following clinical trial:

Trial Title: GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed malignant recurrent glioma\*, including any of the following:~  * Glioblastoma~    * Glioblastoma multiforme~* Recurrent disease or progressive primary disease~* Surgically accessible tumor for which surgical resection is indicated and has not been previously irradiated~* Prior radiotherapy required~* No prior oncophage therapy or immunotherapy for glioma~PATIENT CHARACTERISTICS:~* Karnofsky performance status 80-100%~* Life expectancy ≥ 8 weeks~* Absolute granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Alkaline phosphatase and serum glutamic-pyruvic transaminase (SGPT) \<=2.5 times normal~* Bilirubin \< 1.5 mg/dL~* Blood Urea Nitrogen (BUN) \< 1.5 times normal OR creatinine \< 1.5 times normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for at least 4 weeks after completion of study treatment~* No uncontrolled active infection~* No bleeding diathesis~* No psychiatric or medical situation that would preclude study compliance~* No unstable or severe concurrent medical condition~* No other cancer or concurrent malignancy within the past 5 years except adequately treated nonmetastatic in situ carcinoma of the uterine cervix, nonmetastatic nonmelanoma skin cancer, or in complete remission and off all therapy for that disease~* No systemic autoimmune disease (e.g., Hashimoto's thyroiditis) and/or any history of primary or secondary immunodeficiency~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 2 weeks since prior vincristine~* At least 6 weeks since prior nitrosoureas~* At least 4 weeks since prior temozolomide or other cytotoxic chemotherapy~* At least 4 weeks since prior investigational agents~* At least 1 week since prior noncytotoxic agents~* At least 3 weeks since prior procarbazine~* No radiotherapy within the past 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: Vaccine (Type: EXPERIMENTAL): Patients received 25 micrograms of HSPPC-96 bi-weekly or weekly for the first 4 vaccinations followed by biweekly injections.
- Phase 2: Vaccine (Type: EXPERIMENTAL): Treatment consisted of 25 mcg of HSPPC-96 weekly for at least 4 weeks, followed by biweekly injections (pending vaccine availability) for up to 52 weeks from the date of surgical resection.

Based on this trial design, predict the completion outcome and termination type (if applicable).